Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful pre-treatment testing is essential to ensure safety, effectiveness and long-term ...

GLP-1s are basically appetite’s off-switch: suddenly you’re “full” after three bites. Congrats on the smaller meals and ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

Since we know that eating less food often means getting fewer nutrients, a high-quality multivitamin acts as an insurance ...

The 71-year-old has been taking a GLP-1 (we don’t know which one) since 2023 to lose weight, and says the change in her ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

One of the biggest risk factors for prediabetes is weight gain. Over the past several decades, rates of obesity have risen ...

Our work continues on behalf of TRICARE For Life beneficiaries. Learn the latest, and find out how to share your story with ...

Metabolic surgery was associated with lower all-cause mortality and a lower risk for major adverse cardiac events than GLP-1 receptor agonists (RAs), based on data from a new study of more than 3000 ...